Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

238

Participants

Timeline

Start Date

August 26, 2020

Primary Completion Date

June 6, 2022

Study Completion Date

September 30, 2022

Conditions
Covid-19SARS-CoV2
Interventions
DRUG

BIO101

BIO101 capsules

DRUG

Placebo

placebo capsules

Trial Locations (22)

2800

AZ-Sint Maarten, Mechelen

13903

United Health Services Hospitals, Johnson City

17403

WellSpan Health, York

48073

Beaumont Health, Royal Oak

71457

Barnum Medical Research, Inc. 1029 Keyser Ave Suite H, Natchitoches

75013

Hôpital Pitié-Salpêtrière, 47 bd de l'Hôpital, 75013 Paris, Paris

75651

Unité ambulatoire Service de Pneumologie, Médecine Intensive et Réanimation (SPMIR) 47-83 Boulevard de l'Hôpital, Paris

85015

Abrazo Health, Phoenix

92697

University of California, Irvine, Irvine

Unknown

CHU Saint-Pierre, Brussels

Hospital Vera Cruz, Belo Horizonte

Santa Casa de Porto Alegre, Porto Alegre

Hospital Municipal de Barueri Dr. Francisco Moran, Barueri

Hospital e Maternidade Celso Pierro - PUCCAMP, Campinas

Hospital de Base Da Faculdade de Medicina de São José Do Rio Preto, São José do Rio Preto

Centre Hospitalier Argenteuil, Argenteuil

Centre Hospitalier Universitaire Bordeaux, Bordeaux

Centre Hospitalier Rene Dubos, Cergy-Pontoise

Centre Hospitalier Départemental de Vendée, La Roche-sur-Yon

15 5000

CHU CLU Namur (Saint-Elisabeth) Place Louise Godin, Namur

103.034

Avenida Dr. Enéas de Carvalho Aguiar, 44 - Centro de Pesquisa Clínica Prof. Dr. Fúlvio Pileggi - Bloco 1 - 1º Andar, São Paulo

00927

FDI Clinical Research - San Juan City Hospital, San Juan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biophytis

INDUSTRY